Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Akinori Sugaya"'
Autor:
Mitsuaki Hirose, Masashi Sato, Ichinosuke Hyodo, Mamiko Imanishi, Kenji Yamato, Akinori Sugaya, Xiaoxuan Wang, Toshikazu Moriwaki, Xiaochen Zhang, Shinji Endo, Yoshiyuki Yamamoto
Publikováno v:
Anticancer Research. 41:1475-1483
Background/aim The oncoproteins murine double minute (MDM) 2 and MDM4 inactivate tumor-suppressor protein p53. Their mutual relationship with the prognosis of gastric cancer (GC) remains unknown. Patients and methods Expression of MDM2, MDM4, and p53
Autor:
Ichinosuke Hyodo, Akinori Sugaya, Yoshiyuki Yamamoto, Shunsuke Ueyama, Toshikazu Moriwaki, Takeshi Yamada, Hirosumi Suzuki
Publikováno v:
International Journal of Clinical Oncology. 26:370-377
Nivolumab is a standard later-line therapy for advanced gastric cancer (AGC). However, few reports exist about its efficacy and safety in patients with massive ascites. We retrospectively collected clinical data from 72 AGC patients who received nivo
Autor:
Akinori Sugaya, Toshikazu Moriwaki, Mitsuaki Hirose, Yoshiyuki Yamamoto, Xiaoxuan Wang, Masashi Sato, Yukikazu Natori, Shinji Endo, Xiaochen Zhang, Kenji Yamato, Ichinosuke Hyodo, Mamiko Imanishi
Publikováno v:
Oncology Letters. 22
Murine double minute homolog 2 (MDM2) is an oncoprotein that induces p53 degradation via ubiquitin-ligase activity. MDM4 cooperates with MDM2-mediated p53 degradation, directly inhibiting p53 transcription by binding to its transactivation domain. Ou
Autor:
Mamiko Imanishi, Kenji Yamato, Ichinosuke Hyodo, Mitsuaki Hirose, Yukikazu Natori, Yoshiyuki Yamamoto, Akinori Sugaya, Xiaoxuan Wang, Shinji Endo
Publikováno v:
Cancer Science. 110:639-649
Inactivation of the TP53 tumor suppressor gene is essential during cancer development and progression. Mutations of TP53 are often missense and occur in various human cancers. In some fraction of wild-type (wt) TP53 tumors, p53 is inactivated by upre
Autor:
Xiaoxuan, Wang, Yoshiyuki, Yamamoto, Mamiko, Imanishi, Xiaochen, Zhang, Masashi, Sato, Akinori, Sugaya, Mitsuaki, Hirose, Shinji, Endo, Yukikazu, Natori, Toshikazu, Moriwaki, Kenji, Yamato, Ichinosuke, Hyodo
Publikováno v:
Oncology Letters
Murine double minute homolog 2 (MDM2) is an oncoprotein that induces p53 degradation via ubiquitin-ligase activity. MDM4 cooperates with MDM2-mediated p53 degradation, directly inhibiting p53 transcription by binding to its transactivation domain. Ou
Autor:
AKINORI SUGAYA1,2, SHINGO ISHIGURO1, SHOICHI MITSUHASHI1, MASAHIRO ABE3, IKUTA HASHIMOTO3, TAKAYUKI KABURAGI3, HIROSHI KOJIMA1,4 h-kojima@chubyoin.pref.ibaraki.jp
Publikováno v:
Molecular & Clinical Oncology. 2017, Vol. 6 Issue 2, p229-232. 4p.
Autor:
Yoshiyuki Yamamoto, Akinori Sugaya, Ryosuke Tanaka, Ryuta Sato, Ichinosuke Hyodo, Fumiaki Furuya, Yasuhiro Matsumura, Masahiro Yasunaga, Mitsunori Harada, Ryo Tsumura, Hiroki Takashima, Yoshikatsu Koga
Publikováno v:
Cancer Science
Tissue factor (TF), an initiator of the extrinsic blood coagulation cascade, is overexpressed in different types of cancer. Tissue factor overexpression is also known as a poor prognostic factor in pancreatic cancer. We recently developed anti-TF ant
Autor:
Mamiko Imanishi, Ichinosuke Hyodo, Daisuke Ochi, Shinji Endo, Akinori Sugaya, Yukako Hamano, Toshikazu Moriwaki, Mariko Kobayashi, Daisuke Akutsu
Publikováno v:
Internal Medicine. 55:127-130
Combination chemotherapy of mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) plus panitumumab, a fully human monoclonal antibody against epidermal growth factor receptor (EGFR), is one of the standard treatments for metastatic colorectal cancer
Autor:
Toshikazu Moriwaki, Masahiko Gosho, Akinori Sugaya, Takeshi Yamada, Yoshiyuki Yamamoto, Ichinosuke Hyodo
Publikováno v:
Cancer Research & Treatment; Jul2021, Vol. 53 Issue 3, p703-713, 11p
Autor:
Yoshiyuki Yamamoto, Ichinosuke Hyodo, Akinori Sugaya, Toshikazu Moriwaki, Takeshi Yamada, Hirosumi Suzuki, Shunsuke Ueyama
Publikováno v:
Journal of Clinical Oncology. 38:392-392
392 Background: Nivolumab is a standard of care as the later-line therapy for advanced gastric cancer. However, there are few data about efficacy and safety of nivolumab for pts with malignant ascites. Methods: We conducted a multicenter retrospectiv